Abstract
α4β7 is a prototypic gut integrin that regulates homing of memory and effector T cells to the gut.1 Vedolizumab is an anti-α4β7 monoclonal antibody and is approved by the US Food and Drug Administration to treat ulcerative colitis and Crohn disease (CD). 1
